Compare KLA Corp. (KLAC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Recursion Pharmaceuticals Inc — how do they compare? KLA Corp. trades at $204.58 (market cap $261.92B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: KLA Corp. is far larger — about 144.7× Recursion Pharmaceuticals Inc's market cap, and KLA Corp. pays a 0.46% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| KLAC | RXRX | |
|---|---|---|
Market Cap | $261.92B | $1.81B |
Sector | Technology | Health |
52-Week High | $301.71 | $6.79 |
52-Week Low | $84.39 | $2.84 |
Enterprise Value | $263.17B | $1.33B |
Dividend Yield | 0.46% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
